T-Cell Lymphoma, Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma
Conditions
Keywords
T-Cell Lymphoma, Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma, Oncaspar®, PEG-L-asparaginase and dexamethasone
Brief summary
This is an open-label, single-arm pilot study of Oncaspar® with dexamethasone for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), excluding extranodal NK/T cell lymphoma (ENKTL). Patients will receive up to 8 courses of treatment.
Detailed description
This is an open-label, investigator-initiated, single-arm pilot study. Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) will receive Oncaspar® every 3 weeks up to a maximum of 8 courses or until disease progression or unacceptable toxicity. They will also receive dexamethasone 40mg daily for 4 days with every cycle. They will be restaged after 2 courses (6 weeks) and after 8 courses (24 weeks). Both Oncaspar and dexamethasone have been used together to treat ALL and ENKTL, which is another subtype of T cell lymphoma. The combination may provide a collaborative attack against the cancer cell; moreover, the dexamethasone could also prevent some of the side effects of Oncaspar; especially allergic reactions. This study will test these two drugs together to determine if they are an effective treatment for T-Cell Lymphoma. Each drug is commercially available to the drug market.
Interventions
-dexamethasone 40mg daily for 4 days with every cycle.
Sponsors
Leadiant Biosciences, Inc.
Dana-Farber Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients must meet the following criteria on screening examination to be eligible to participate in the study: * Patients must have histologically confirmed peripheral T-cell lymphoma, with the diagnostic specimen reviewed at one of the DFHCC hematopathology laboratories. Eligible histologies include: * PTCL-NOS * Systemic T cell/null anaplastic large cell lymphoma (ALCL), regardless of Alk status * Angioimmunoblastic T-cell lymphoma (AITL) * Hepatosplenic (alpha-beta or gamma-delta) lymphoma (HSL) * Enteropathy-associated T-cell lymphoma (EATL) * Adult T-cell leukemia/lymphoma (ATLL), lymphomatous subtype * Subcutaneous panniculitis-like T-cell lymphoma * T-cell Prolymphocytic Leukemia (T-PLL) * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \> 20 mm with conventional techniques or as \> 10 mm with spiral CT scan * Patients must have relapsed or progressed after at least 1 prior course of anti-lymphoma therapy. * Age 18-65 years. * ECOG performance status \<2 (see Appendix A). * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Patients who exhibit any of the following conditions at screening will not be eligible for admission into the study. * Patients with cutaneous disease only are not eligible. * Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier to grade 1 or below (unless approved by the Study Chair). * Patients may not be receiving any other study agents at the time of first treatment. * History of treatment with an asparaginase agent. * Patients with a history of alcohol abuse, or patients unwilling or unable to remain completely abstinent of alcohol during the study period. * Hepatitis B or C seropositivity (except for hepatitis B with negative surface antigen and hepatitis B viral load). * Total bilirubin \> institutional upper limit of normal (ULN), unless due to hemolysis or Gilbert's disease). * AST/ALT ≥ 3 x ULN. * History of pancreatitis, or amylase \> ULN or lipase \> ULN. * History of thromboembolic disease. * Grade 2 or above neuropathy. * Diabetes mellitus, unless it is type II diabetes adequately controlled with anti-diabetic agents (A1c \< 7). * History of CNS hemorrhage or thrombosis. Patients with a history of CNS lymphomatous involvement are eligible only if their CNS disease is in remission at the time of study entry. * Uncontrolled intercurrent illness including, but not limited to uncontrolled active infection, symptomatic congestive heart failure (New York Hospital Association (NYHA) class II-IV, resulting in at least slight limitation of activity), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Inability to provide informed consent * Pregnancy or lactation. * Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin. * HIV-positive individuals on combination antiretroviral therapy are ineligible.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate (complete + partial response) in evaluable patients. | 24 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Grade 2 and above attributable toxicity of treatment. | 24 weeks | — |
| Progression-free survival. | 1 year | This will be assessed in both evaluable patients and in responders. |
| Complete remission (CR) rate. | 24 weeks | This will be assessed both in the intent-to-treat and in the evaluable populations. |
| Partial remission (PR) rate. | 24 weeks | This will be assessed both in the intent-to-treat and in the evaluable populations. |
| Duration of response for patients with PR or CR | 24 weeks | — |
| Progressive disease (PD) rate. | 24 weeks | This will be assessed both in the intent-to-treat and in the evaluable populations. |
| Stable disease (SD) rate. | 24 weeks | This will be assessed both in the intent-to-treat and in the evaluable populations. |
| Overall survival | 1 year | This will be assessed in both evaluable patients and in responders. |
| The stable disease (SD) rates in this population and in the intent-to-treat population | 24 weeks | — |
Countries
United States
Outcome results
None listed